NEW ORLEANS -- Treatment with investigational elecoglipron led to weight loss in people with obesity and improved glucose control in those with type 2 diabetes, a pair of global phase II randomized trials showed.
In the dose-ranging VISTA study of adults with obesity or overweight without diabetes, mean body weight loss by week 26 ranged from 2.6% in the 5 mg elecoglipron group to 10.5% in the 75 mg group with weekly titration steps, compared with 0.6% weight loss with placebo.
In an extension phase that spanned to week 36, weight loss reached up to 11.8% with the 75 mg weekly titration dose compared with a 0.3% loss with placebo, reported Melanie Davies, MD, of the University of Leicester in England.
The weight loss had not yet plateaued, Davies said at the American Diabetes Association (ADA) annual meeting. The findings were simultaneously published in The Lancet.
Elecoglipron is an oral, small-molecule GLP-1 receptor agonist, similar to the recently approved once-daily weight-loss pill orforglipron (Foundayo). Both carry no food or fluid dosing restrictions, setting them apart from oral semaglutide (Wegovy), which needs to be taken with water in the morning on an empty stomach.
